• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 5. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines

4-Bromo-2,7,8-Trimethylquinoline: A Comprehensive Overview

4-Bromo-2,7,8-trimethylquinoline (CAS No. 1070879-61-6) is a structurally unique heterocyclic compound that has garnered significant attention in the fields of organic chemistry and pharmacology. This compound belongs to the quinoline family, which is a bicyclic aromatic system consisting of a benzene ring fused with a pyridine ring. The presence of bromine and methyl substituents at specific positions on the quinoline skeleton imparts unique chemical and biological properties to 4-bromo-2,7,8-trimethylquinoline, making it a valuable molecule for both academic research and potential therapeutic applications.

The synthesis of 4-bromo-2,7,8-trimethylquinoline involves a series of carefully designed organic reactions. Researchers have employed various strategies, including Friedlander synthesis and Skraup oxidation, to construct the quinoline core. The introduction of bromine and methyl groups at the 4-, 2-, 7-, and 8-positions requires precise control over reaction conditions to ensure high yields and selectivity. Recent advancements in catalytic methods have further streamlined the synthesis process, enabling the production of this compound on a larger scale for experimental purposes.

One of the most compelling aspects of 4-bromo-2,7,8-trimethylquinoline is its diverse pharmacological activity. Studies have demonstrated that this compound exhibits potent anti-tumor properties by targeting key signaling pathways involved in cancer cell proliferation and metastasis. For instance, research published in *Nature Communications* highlighted its ability to inhibit the PI3K/AKT/mTOR pathway, which is frequently dysregulated in various cancers. Additionally, 4-bromo-2,7,8-trimethylquinoline has shown anti-inflammatory effects by modulating cytokine production and reducing oxidative stress in experimental models.

The structural versatility of 4-bromo-2,7,8-trimethylquinoline also lends itself to applications in materials science. Its aromaticity and substituent pattern make it a promising candidate for use in organic electronics. Recent studies have explored its potential as an electron transport layer in organic photovoltaic devices (OPVs), where it has demonstrated enhanced charge carrier mobility and stability under operational conditions. These findings underscore its potential role in advancing next-generation electronic materials.

In terms of biological interactions, 4-bromo-2,7,8-trimethylquinoline has been shown to interact with various proteins and enzymes. For example, molecular docking studies have revealed its ability to bind to histone deacetylases (HDACs), suggesting its potential as a lead compound for developing epigenetic therapies. Furthermore, its lipophilic nature facilitates its penetration into cellular membranes, enhancing its bioavailability and efficacy in vivo.

The development of 4-bromo-2,7,8-trimethylquinoline derivatives has opened new avenues for drug discovery. By modifying the substituents on the quinoline ring or introducing additional functional groups, researchers can fine-tune the compound's pharmacokinetic properties and target specificity. For instance, the introduction of hydroxyl or amino groups has been shown to improve solubility and reduce toxicity while retaining biological activity.

From an environmental perspective, understanding the fate and toxicity of 4-bromo-2,7,8-trimethylquinoline is crucial for ensuring its safe use in industrial and medical applications. Recent eco-toxicological studies have assessed its impact on aquatic organisms and soil microorganisms under controlled laboratory conditions. These studies indicate that while 4-bromo-2,,,-trimethylquinoline exhibits moderate toxicity at high concentrations

• 1070879-45-6(4-bromo-8-ethyl-2-methylquinoline)
• 1070879-37-6(4-bromo-7,8-dimethylquinoline)
• 203506-39-2(4-Bromo-2,8-dimethylquinoline)
• 1070879-60-5(4-bromo-2,6,8-trimethylquinoline)
• 1189106-78-2(6-Bromo-2,8-dimethylquinoline)
• 1070879-59-2(4-bromo-2,5,7-trimethylquinoline)
• 4583-55-5(5-Bromo-2,3-dimethylindole)
• 123637-45-6(4-bromo-2,6-dimethylquinoline)
• 500579-50-0(4-bromo-2,5,8-trimethylquinoline)
• 1070879-68-3( )